CoChat

Early Insulin Use in Type 2 Diabetes

Open access
Chiasson, Jean-Louis · 2009 · Diabetes Care

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

It is generally recognized that type 2 diabetes is one of the major challenges of the 21st century. Its prevalence is growing rapidly worldwide, particularly in developing countries (1). It remains the first cause of blindness, end-stage renal disease, and nontraumatic lower-limb amputation and one of the major causes of cardiovascular disease (2,3). Because of its high morbidity and excess mortality, it has become a tremendous burden on health care cost (4). In the last decade, a number of interventions have been shown to be effective in the prevention of diabetes in high-risk populations with impaired glucose tolerance and/or impaired fasting glucose (5–7). Yet, few countries have adopted policies for the screening and strategies for treating subjects with pre-diabetes. Furthermore, despite the development of newer therapies for treatment of diabetes, the disease is still associated with a high incidence of microangiopathy and macrovascular complications. Any new strategies that could help to curtail the burden of diabetes would be greatly appreciated. More recently, it was postulated that early insulin replacement in type 2 diabetes, and perhaps even in pre-diabetes, may reduce cardiovascular risk and may even offer protection for the β-cell (8,9). However, a closer look at the available data does not support the hypothesis. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study is still ongoing and therefore does not allow any conclusion in pre-diabetes. In type 2 diabetes, however, the published data support neither a beneficial effect of insulin therapy per se on microvascular complications, nor on cardiovascular events and mortality. In addition, the data suggesting that insulin therapy can improve the β-cell response to a glucose challenge could just as well be interpreted as being due to the improvement in glycemic control, rather than to the insulin therapy. And finally, …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-s321

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The relationship between A1C and the incidence of microvascular end points and myocardial infarction. Reproduced with permission from Stratton et al. (13).
Figure 1 The relationship between A1C and the incidence of microvascular end points and myocardial infarction. Reproduced with permission from Stratton et al. (13).CC BY-NC-ND · PubMed Central
Figure 2 Changes in blood glucose (BG) and plasma insulin (immunoreactive insulin [IRI]) during a 100-g glucose tolerance test before and after treatment with diet only, sulfonylurea (SU), or insulin of overtly diabetic patients (mean ± SD) according to the initial sum of blood glucose. Number in parentheses indicates number of patients before treatment (●) and after treatment (○). Reproduced with permission from Kosaka et al. (21).
Figure 2 Changes in blood glucose (BG) and plasma insulin (immunoreactive insulin [IRI]) during a 100-g glucose tolerance test before and after treatment with diet only, sulfonylurea (SU), or insulin of overtly diabetic patients (mean ± SD) according to the initial sum of blood glucose. Number in parentheses indicates number of patients before treatment (●) and after treatment (○). Reproduced with permission from Kosaka et al. (21).CC BY-NC-ND · PubMed Central
Figure 3 The prevalence of severe hypoglycemia in relation to the duration of type 2 diabetes. Adapted from Henderson et al. (22).
Figure 3 The prevalence of severe hypoglycemia in relation to the duration of type 2 diabetes. Adapted from Henderson et al. (22).CC BY-NC-ND · PubMed Central
Figure 4 The relative risk of colorectal cancer in relation to the duration of insulin therapy in type 2 diabetes. Adapted from Yang et al. (29).
Figure 4 The relative risk of colorectal cancer in relation to the duration of insulin therapy in type 2 diabetes. Adapted from Yang et al. (29).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 24

Metadata

Authors
Chiasson, J.-L.
Affiliations
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author
Chiasson, Jean-Louis
Venue
Diabetes Care
Published
2009-11-01
Volume
32
Issue
suppl_2
Pages
S270-S274
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2108706134
Cited by
24
References
31
Citations by year
2025: 1 · 2024: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, early insulin therapy, insulin replacement therapy, prediabetes, impaired glucose tolerance, impaired fasting glucose, cardiovascular risk, microvascular complications, beta-cell function, ORIGIN trial, glycemic control, diabetes prevention
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Microcirculation, Risk, Sulfonylurea Compounds, Colorectal Neoplasms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.